Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,644.80up ₹17.30 (1.06%)BSE ₹1,640.10
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,627.50.
28 Oct: open ₹1,625.00, high ₹1,650.00, low ₹1,609.10
52-week range of traded prices to 28 Oct 2026
₹1,081.40Low, 28 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹94,638 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.49
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,54,48548.5% delivered
Aurobindo Pharma disputes and clarifications
28 filed, newest first.
Feb 2026
Jan 2026
31 Jan · Legal
The exchange asked on 30 Jan 2026
Jun 2025
6 Jun · Legal
Apr 2025
30 Apr · Legal
Mar 2025
1 Mar · Legal
Feb 2025
5 Feb · Legal
Jan 2025
29 Jan · Legal
Dec 2024
13 Dec · Legal
Nov 2022
10 Nov · Legal
Exchange has sought clarification from Aurobindo Pharma Limited with respect to announcement dated 10-Nov-2022 informing about arrest of Mr. P. Sarath Chandra Reddy, Whole Time Director / Promoter Group of the Company.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Whether such fraud/default/arrest has been reported to appropriate authorities. 2. Nature of fraud/default/arrest; 3. Estimated impact on the listed entity; 4. Time of occurrence; 5. Person(s) involved; 6. Estimated amount involved (if any); The response of the company is awaited.
May 2019
13 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned- titled "Pharma stocks bleed as US states file lawsuit against generic drug firms". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company was aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Apr 2019
Mar 2019
Apr 2017
19 Apr · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned "US FDA Issues 5-6 'Largely Procedural' Observations To Aurobindo Pharma's Unit-III". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Dec 2016
14 Dec · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Blast at Aurobindo Pharma's Andhra unit, two dead , one injured critically In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Nov 2016
22 Nov · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Vietnam Government blacklists Aurobindo Pharma on quality issues. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Apr 2015
8 Apr · Legal
Exchange has sought clarification from Aurobindo Pharma Limited with reference to recent news item captioned "Aurobindo pharma alleges fraud by owners of Natrol bought by the company from Plethico pharma, contracts worth $25mn. were fictitious". In this regard, The Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
24 Dec · Legal
Exchange had sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "AstraZeneca sues Aurobindo over blood sugar drug patent". The Company has clarified that : Aurobindo had filed an ANDA for Saxagliptin tablets certifying P-IV against the relevant patents listed in US FDA Orange Book. Based on this, Astrazeneca had filed a case in a US District Court against Aurobindo. It is usual practice for an innovator company to file law suit against a generic company who files an ANDA with a P-IV certification for a particular product. Aurobindo is responding to the complaint appropriately within the stipulated time frame. This matter is subjudice and will not have any material impact on the Company.24 Dec · Legal
Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "AstraZeneca sues Aurobindo over blood sugar drug patent". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
18 Nov · Legal
Exchange had sought clarification from Aurobindo Pharma Limited with respect to a news item captioned "Aurobindo Pharma to spend Rs. 1,300 corore in capex". The Company has clarified that "The Company as a good corporate governance practice organizes analyst calls with management to discuss on the published quarterly results. The said news in the media has been captured from the transcript of the call pertaining to second quarter FY 14-15 earnings, held on November 07, 2014 and as published on our website. We have consistently stated that the Company s CapEx including maintenance CapEx is expected to be around Rs.600 crores for FY 2014-15, which will be spread out across APIs and Formulations. It is our broad estimation that CapEx in FY 2015-16 will be around Rs.600 to 700 crores, depending upon the cash flows and on review of CapEx needs. We consider that the news appearing in the media is incorrect and misinterpreted and does not require disclosure under clause 36 of the listing agreement, as this is nothing different than what we have been sharing in the past. We also as a policy do not comment on the media reports and market speculations".18 Nov · Legal
Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "Aurobindo Pharma to spend Rs. 1,300 corore in capex". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Jan 2014
Sep 2012
14 Sep · Legal
Dated September 14, 2012 that "In response to news appearing in certain section of the press about Aurobindo considering restructuring by way of sale of some of its unit(s) or verticals is completely groundless, false and untrue. We completely deny all these rumors and caution all shareholders and investors not to take cognizance of these rumors. Aurobindo prides itself of its strong vertical integration and will continue to unleash potential of its vertical integration to market leadership and competitiveness".